Reuters
19 Nov 2026, 21:37 UTC · 1h ago
Celldex ends eczema drug development after mid-stage trial failure
Impact · against what's priced in
Celldex shares face downward pressure following the total cessation of its eczema drug development. The mid-stage trial failure removes a potential pipeline asset and long-term revenue catalyst.
- CLDX−0.80
No priced-in read yet
- In context
The company is halting development of its experimental eczema drug after it failed to meet primary and key secondary study goals, eliminating a future growth opportunity.
Read from the article alone

Top 1 mover · tap to explore




